NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp
MWN-AI** Summary
NAMSA, a prominent global leader in medical device testing and regulatory consulting, has announced the strategic acquisition of select assets from Labcorp's Early Development medical device testing business. This acquisition enhances NAMSA's capacity to support medical technology (MedTech) manufacturers by providing a broader portfolio of services, including biocompatibility, microbiological, and analytical testing, as well as preclinical research.
The deal allows NAMSA to build on its existing relationships with over 3,000 MedTech companies worldwide, aiming to streamline the product development process and accelerate time-to-market for clients. Brian Smith, NAMSA’s CEO, emphasized that the integration of Labcorp's offerings positions NAMSA as a comprehensive partner in medical device development, ensuring a smooth transition for Labcorp’s customers while maintaining the high standards of service that NAMSA is known for.
Labcorp, known primarily for its laboratory services, indicated that this sale aligns with its strategy to focus on core areas of drug development and chemical testing. Brian Caveney, Labcorp's Executive Vice President, pointed out that NAMSA's expertise would benefit clients in the early development space, ensuring continuity and excellence in the testing services provided.
This acquisition marks the tenth for NAMSA since it became part of ARCHIMED, a healthcare-focused private equity firm, in 2020. The agreement not only reflects NAMSA’s dedication to expanding its capabilities in medical device testing, but also highlights the firm’s ongoing commitment to innovation and regulatory compliance in the MedTech industry. With facilities across the U.S., Europe, and Asia, NAMSA aims to utilize its extensive expertise to facilitate and enhance the medical device development lifecycle for its expanded client base.
MWN-AI** Analysis
The recent acquisition of select assets from Labcorp’s Early Development medical device testing business by NAMSA is a significant strategic move that strengthens NAMSA's position in the MedTech landscape. This acquisition not only expands NAMSA's service portfolio to include biocompatibility testing, microbiological testing, and analytical testing but also consolidates its role as a comprehensive partner for MedTech manufacturers worldwide.
For investors, this acquisition suggests a bullish outlook for NAMSA. The integration of Labcorp's assets positions NAMSA to accelerate client offerings and enhance operational efficiencies, which could lead to improved revenue growth. With Labcorp focusing on its core preclinical drug development operations, NAMSA can tap into a specialized client base that requires its extensive expertise, thus facilitating a smoother transition and potentially increasing customer retention and satisfaction.
In the context of market dynamics, the acquisition highlights a growing demand for streamlined testing and regulatory consulting services in the MedTech industry. The increasing emphasis on innovation in medical devices aligns with NAMSA's strategic focus, making it a compelling choice for investment. Companies that are proactive in expanding their service offerings, particularly in a niche field like medical device testing, often emerge as frontrunners in market share and profitability.
Investors should watch for NAMSA's performance indicators, particularly in client acquisition and revenue post-acquisition. Given the company's established track record and the backing of ARCHIMED, a healthcare-focused investment firm, NAMSA is poised for significant growth. This strategic move is likely to enhance its competitive edge, making it a stock to consider for investors looking to capitalize on the expanding MedTech sector. As always, thorough due diligence is recommended before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide.
As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Early Development medical device testing business, including biocompatibility testing, microbiological testing, analytical testing, and preclinical research.
This acquisition strengthens NAMSA's position as the industry's most comprehensive innovation partner for end-to-end medical device development, enabling clients to access expanded expertise and streamlined solutions across the product lifecycle.
Brian Smith, CEO of NAMSA notes: "This acquisition is a perfect fit for NAMSA - we serve 3,000+ MedTech companies globally in these specific areas of testing and preclinical research. I am confident we will be able to provide Labcorp's medical device clients with a smooth transition combined with the same high level of expertise and customer service current NAMSA clients have come to expect from us."
NAMSA provides medical device testing, preclinical and clinical services, combined with comprehensive regulatory consulting to MedTech companies worldwide. The company has locations in the U.S., Europe and Asia. Future testing and preclinical projects for Labcorp's Early Development medical device clients will be performed at existing NAMSA facilities in Ohio, Minnesota, Georgia and California.
"The sale of our Early Development medical device testing business to NAMSA allows Labcorp to focus on core areas of preclinical drug development and chemical testing," said Brian Caveney, M.D., EVP and President, Early Development Research Laboratories, Labcorp. "We are pleased NAMSA will continue providing leading expertise to clients in this space and are committed to a seamless transition."
NAMSA is an ARCHIMED company; acquired by the healthcare-focused global private equity firm in 2020. This acquisition is NAMSA's 10th acquisition since becoming an ARCHIMED company.
About NAMSA
Helping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development. From preclinical and clinical research to medical device testing and regulatory compliance, NAMSA is the industry's trusted partner for successful development and commercialization outcomes.
Learn more at namsa.com
About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation. Learn more at archimed.group
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the sale of Labcorp's Early Development medical device testing business to NAMSA and the potential benefits of the transaction. Actual results could differ materially from those suggested by forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Media Contacts:
NAMSA Media Contact
Chris Schorre
Senior Director of Global Marketing
Email: communications@namsa.com
SOURCE NAMSA
FAQ**
How does the acquisition of Labcorp’s Early Development medical device testing business enhance NAMSA's capabilities in biocompatibility testing and preclinical research for MedTech companies?
What strategies does NAMSA plan to implement to ensure a seamless transition for Labcorp's Early Development medical device clients post-acquisition?
In light of this acquisition, how does NAMSA aim to further differentiate itself in the competitive landscape of medical device testing services against other players like Laboratory Corporation of America Holdings LH?
Given NAMSA's history of acquisitions under ARCHIMED, what specific growth opportunities does this acquisition present for expanding its market share in the medical device testing industry?
**MWN-AI FAQ is based on asking OpenAI questions about Laboratory Corporation of America Holdings (NYSE: LH).
NASDAQ: LH
LH Trading
-0.64% G/L:
$269.325 Last:
210,684 Volume:
$270 Open:
